Background
Testicular cancer survivors, many of whom have undergone radiotherapy, are at substantial risk of second cancers. Treatment for testicular cancer may limit treatment options for second cancers, thereby adversely affecting survival after the second cancer. However, no data on outcomes of testicular cancer survivors with second cancers compared to patients with comparable first cancers exist.
Methods
Among 29 356 white testicular cancer patients reported to the Surveillance, Epidemiology, and End Results (SEER) program (1973 -2002) , 621 developed a second cancer with known stage and were matched to a random sample of 12 420 white male first cancer patients in the SEER program by cancer site, stage, diagnosis year, and age at diagnosis. Mortality was ascertained through 2002. Cancer-specific and all-cause mortality following second cancers were compared with those of matched first cancers, and rate ratios (RRs) were estimated using proportional hazards analysis. Survival functions were calculated using product-limit estimates.
Results
During the study period, 284 testicular cancer survivors with second cancers died, 191 from their second cancer; 5443 matched first cancer patients died, 3929 from their first cancer. Rate ratios for cancer-specific and all-cause mortality for second cancers compared with matched first cancers were 1.05 (95% confidence interval [CI] = 0.90 to 1.23) and 1.09 (95% CI = 0.96 to 1.23), respectively. However, among testicular cancer patients who were diagnosed during 1973 -1979 , an era in which radiation therapy was given at high doses and to the chest area, all-cause mortality following second cancers at sites below the diaphragm (79 deaths) and second lung cancers (29 deaths) was statistically significantly higher than that from matched first cancers (RR = 1.44, 95% CI = 1.13 to 1.83, and RR = 1.65, 95% CI = 1.12 to 2.42, respectively).
may be limited by radiation-induced fi brosis ( 8 ) and impaired wound healing ( 9 ) . In addition, mechanisms of therapy-related carcinogenesis, such as genomic instability caused by mutations in DNA repair genes ( 10 ) , may negatively affect the response of second cancers to treatment ( 11 ) .
To determine whether mortality following a second cancer among testicular cancer survivors differs from mortality following comparable fi rst cancers in the general population, we compared cancer-specifi c and all-cause mortality among 621 white testicular cancer survivors with second cancers to mortality among a random sample of 12 420 age-matched white male patients with fi rst cancers of the same anatomic site, stage, and calendar year of diagnosis. To evaluate any infl uence of different management strategies on patient mortality, we did not match patients by cancer treatment. All study subjects were identifi ed from population-based cancer registries within the National Cancer Institute ' s Surveillance, Epidemiology, and End Results (SEER) program.
Subjects and Methods
The underlying cohort from which second cancer patients were identified consisted of 29 356 white men who were diagnosed with a first primary invasive testicular germ cell tumor [International Classification of Diseases for Oncology, Third Edition (ICD-O-3) codes C62.0 -C62.9; histology codes 9060 -9062 (seminoma) and 9070 -9073, 9080 -9085, and 9100 -9102 (nonseminoma) ( 12 ) ] between January 1, 1973, and December 31, 2002 , that was reported to 15 population-based SEER program registries and who survived for at least 2 months ( 13 ) . Testicular cancer with histology code 9063 (spermatocytic seminoma) was excluded. The SEER program registries include approximately 26% of the US population ( 3 ). The cohort was limited to white men due to the rarity of this tumor among other racial and ethnic groups. Excluding second testicular cancers and Kaposi sarcoma, 621 testicular cancer patients subsequently developed a second primary invasive nonlymphohematopoietic cancer; stage was recorded for 590 (95%) of these patients. An additional 31 testicular cancer patients developed leukemia other than chronic lymphocytic leukemia. Second cancers were diagnosed from March 1, 1973 We compared the age, calendar year, and stage distribution of the 621 second cancers in testicular cancer patients with the distribution for fi rst nonlymphohematopoietic invasive cancers with recorded stage and non-chronic lymphocytic leukemias identifi ed from the same population-based registries. Second cancers were diagnosed on average at an earlier age (55.4 years versus 65.9 years), a later calendar year (1995 versus 1992), and an earlier stage (46% versus 40% localized for nonlymphohematopoietic tumors other than prostate cancer) than comparable fi rst cancers. Therefore, for each of the 621 second cancers, we selected 20 fi rst cancers at random without replacement with the same values for the following variables: 1) SEER program site recode (based on ICD-O-3 anatomic site and histology) ( 13 ), 2) SEER program historic stage A (local, regional, or distant) ( 14 ), 3) age at diagnosis (matched within 5-year intervals), and 4) calendar year of diagnosis (matched within 5-year intervals). For some rare sites (i.e., rectum, brain, anus, retroperitoneum, other male genital organs, ureter, other urinary, acute monocytic leukemia, other leukemia, and aleukemic, subleukemic, and leukemia not otherwise specifi ed), criteria for age and calendar year were relaxed to identify a sufficient number of matches. A total of 12 420 matched fi rst cancers were included in the analysis; 95% of both the second cancers and the matched fi rst cancers were histologically confi rmed.
We attributed cause of death for the 621 second cancers and 12 420 fi rst cancers to the specifi c incident cancer if one of the following criteria was met: 1) the SEER program mortality site recode for cause of death (based on International Classifi cation of Diseases, Eighth, Ninth, and Tenth Revisions) ( 15 -17 ) and the site recode for the cancer were identical; 2) the site recodes for mortality and cancer were not identical, but one was a general version of the other (e.g., "other oral cavity and pharynx" compared with tongue) or the two sites are diffi cult to distinguish (e.g., sigmoid
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Prior knowledge
Survivors of testicular cancer are at high risk of developing second cancers.
Study design
Comparison of cancer and all-cause mortality among testicular cancer survivors who developed second cancers and patients with matched first cancers using data from the Surveillance, Epidemiology, and End Results program from 1973 to 2002. Separate analyses were performed for testicular cancer survivors who were diagnosed with testicular cancer during 1973 -1979, when high-dose radiation therapy was common and irradiation to the chest area was a treatment option.
Contribution
Cancer-specific and all-cause mortality were similar between the groups overall. However, for diagnoses during 1973 -1979, all-cause mortality among testicular cancer survivors with second cancers of the lung and at sites below the diaphragm was higher than that among patients with first cancers at these anatomic sites.
Implications
The mortality of testicular cancer survivors with second cancers was similar to that of patients with matched first cancers, but it was higher among testicular cancer survivors who were diagnosed with testicular cancer during 1973 -1979 who developed second cancers at sites that were likely to have been in the radiotherapy treatment field during treatment for testicular cancer.
Limitations
The number of second cancers was small, and details of the treatments patients received and lifestyle risk factors were not available.
Downloaded from https://academic.oup.com/jnci/article-abstract/99/16/1248/975534 by guest on 10 January 2019 colon versus rectum); 3) the mortality site recode represented the same organ system (as specifi ed by ICD-O-3) as the cancer site recode and there were no higher order cancers (third or higher cancers for testicular cancer survivors; second or higher cancers for fi rst cancer patients) with the same site recode as the cause of death; 4) the mortality site recode was not in the same organ system as the cancer site recode, but the sites were in close proximity (e.g., "other oral cavity and pharynx" and esophagus; pleura and lung), and there were no subsequent cancers with the same site recode as the cause of death; or 5) the mortality site recode was "miscellaneous cancer" or "unknown neoplasm," and there were no subsequent cancers identifi ed in the SEER program database. In 91% of the instances among which the cause of death was determined to be due to the cancer of interest, criteria specifi ed in categories 1 or 2 were met for both the second and fi rst cancers. Third-order (n = 44), fourth-order (n = 1), and fi fth-order (n = 1) cancers were identifi ed among 46 (7%) testicular cancer patients with a second cancer, and second-order (n = 781), third-order (n = 54), fourth-order (n = 5), and fi fth-order (n = 1) cancers were identifi ed among 841 (7%) patients with a fi rst cancer. We used a similar algorithm to identify death due to higher order cancers. Some deaths due to cancer could not reasonably be attributed to any of the incident cancers identifi ed in the SEER program database and may either refl ect metastatic sites that were erroneously coded as new cancers or subsequent cancers that were not reported to SEER program registries. Deaths from higher order and unidentifi ed cancers were included only in analyses of all-cause mortality and were not considered as deaths from the second or matched fi rst cancers.
For some analyses, we divided second cancers following testicular cancer into four groups: 1) those that were located in standard subdiaphragmatic radiotherapy fi elds for testicular cancer during the study period (N = 367): stomach (n = 11), small intestine (n = 1), colon (n = 49), rectum (n = 33), anus (n = 3), liver (n = 4), other biliary (n = 2), pancreas (n = 27), retroperitoneum (n = 3), other digestive organs (n = 1), prostate (n = 130), other male genital organs (n = 1), bladder (n = 64), kidney (n = 35), ureter (n = 2), and other urinary organs (n = 1); 2) those that were located in the thoracic radiotherapy fi eld for testicular cancer ( 17 ) (N = 102): esophagus (n = 8), lung (n = 89), and pleura (n = 5); 3) other nonhematologic cancers (N = 121): oral cavity and pharynx (n = 28), larynx (n = 10), soft tissue including heart (n = 10), malignant melanoma (n = 57), brain and other nervous system (n = 1), thyroid (n = 14), and miscellaneous malignant cancer (n = 1); 4) leukemias (N = 31): acute lymphoblastic leukemia (n = 1), other lymphocytic leukemia (n = 3), acute myeloid leukemia (n = 18), chronic myeloid leukemia (n = 4), acute monocytic leukemia (n = 2), other acute leukemia (n = 1), aleukemic, subleukemic, and not otherwise specifi ed (n = 2). First cancers were similarly divided into these groups.
The SEER program routinely collects data on the initial course of cancer treatment in terms of broad categories, such as radiotherapy, chemotherapy, or surgery. Data on radiotherapy fi elds or specifi c cytotoxic drugs are not recorded, and information is not collected with regard to subsequent courses of treatment. Substantial changes in the treatment of testicular cancer have occurred since the late 1970s, with the elimination of thoracic radiotherapy and reductions in the size and administered doses of irradiation to subdiaphragmatic fi elds ( 18 ) . Therefore, in the absence of detailed data on specifi c treatment regimens, we accounted for gradual changes in testicular cancer treatment over time by grouping second cancers according to the calendar year of antecedent testicular cancer diagnosis, i.e., 1973 -1979, 1980 -1989, and 1990 -2002 . For example, in a prior analytic study of testicular cancer patients undertaken in population-based cancer registries ( 5 ), it was estimated that approximately 16% of patients received chest radiotherapy in the 1970s but that few, if any, received thoracic irradiation after 1979. We therefore also conducted selected analyses of second cancers in the radiotherapy fi eld for testicular cancer among those whose fi rst course of treatment for testicular cancer was known to include radiotherapy.
Statistical Analysis
Mortality was assessed from the date of second cancer diagnosis and the date of first cancer diagnosis for the matched sample to whichever date occurred first: death, loss to follow-up, or end of study (December 31, 2002) .
Hazard rate ratios (RRs) of death from second cancers (henceforth referred to as cancer-specifi c mortality) and from all causes (henceforth referred to as all-cause mortality) were compared with those in the sample of fi rst cancers using Cox proportional hazards regression models ( 19 , 20 ) . All models were stratifi ed on the matching factors, namely site of cancer (when analyses included more than one site), stage at diagnosis (localized, regional, distant for nonlymphohematopoietic malignancies other than prostate cancer; localized, regional/distant for prostate cancer, and unstaged for non-chronic lymphocytic leukemias), age at diagnosis (in 5-year intervals), and calendar year of diagnosis (in 5-year intervals). Analyses were also conducted with additional stratifi cation on initial treatment for second and fi rst cancers (surgery alone, radiation with no chemotherapy, chemotherapy with no radiation, radiation and chemotherapy, other). The number of months since diagnosis of the second and fi rst cancers was used as the time metric for the proportional hazards analyses. The proportional hazards assumption was assessed by plotting the log-minus-log of the survival distribution functions; no serious violations were noted. The Wald test was used to test for heterogeneity in rate ratios according to categories of covariates ( 20 ) .
Survival functions were calculated according to months since diagnosis of the second cancer and the sample of fi rst cancers using product-limit estimates without stratifi cation on the matching variables. However, the two groups were exactly balanced on the matching variables. The log-rank test was used to test for the statistical signifi cance of differences in survival functions ( 20 ) .
Pearson's chi-square tests were used to compare the treatment distributions of second cancers and the sample of fi rst cancers ( 20 ) . All statistical tests were two-sided, with a .05 level for statistical signifi cance.
Results
The 621 second cancers were diagnosed an average of 10.6 years after the testicular cancer diagnosis (range = 2 months to 28.9 years). The majority (56.8%) of second cancers occurred among men with localized testicular cancer ( Table 1 ) . For 389 patients (62.6%), initial management of testicular cancer included radiotherapy; 84 (13.5%) were administered chemotherapy alone.
The average duration of follow-up after second cancer diagnosis was 3.9 years (range = <1 month to 22.8 years) and that after fi rst cancer diagnosis was 3.8 years (range = <1 month to 29.2 years). Overall, 284 second cancer patients died during the followup period, with 191 (67%) of the deaths due to the second cancer. A total of 5443 fi rst cancer patients died during the follow-up period; 3929 (72%) of the deaths were attributed to the fi rst cancer.
By design, distributions of the matching variables (stage, age at diagnosis, and calendar year of diagnosis) were similar for second cancers and the matched fi rst cancers ( Table 2 ) . Approximately 46% of all tumors (excluding prostate cancer and leukemia) were localized at diagnosis, 35.4% were regional, and 18.5% were distant. Approximately 78% of cancers were diagnosed from ages 40 -69 years, and 65% were diagnosed since 1994. Initial course of treatment, which was not a matching factor, differed statistically signifi cantly between the second and fi rst cancers ( P = .04); a higher percentage of second cancers were treated by surgery only (49.6% versus 44.4%) and a smaller percentage with radiotherapy and chemotherapy (8.5% versus 11.7%).
We compared cancer-specifi c and all-cause mortality and median survival among second cancer and matched fi rst cancer patients ( Table 3 ) . Rate ratios are adjusted for stage, age, calendar period of diagnosis, and cancer site (when analyses included more than one site). The rate ratios for overall cancer-specifi c and allcause mortality were 1.05 (95% confi dence interval [CI] = 0.90 to 1.23) and 1.09 (95% CI = 0.96 to 1.23), respectively. Small and non -statistically signifi cant elevations in mortality from second cancers of the colon/rectum/anus, pancreas, kidney, lung, and acute myeloid leukemia were evident; conversely, there were non -statistically signifi cant reductions in mortality from second cancers of the stomach and bladder but a non -statistically significant increase for all-cause mortality after a second bladder cancer. Adjustment for differences in initial course of treatment for fi rst and second cancers did not substantially change the rate ratio estimates (data not shown). Although median survival differed by cancer site, there were no statistically signifi cant differences in survival between fi rst and second cancers of the same anatomic site . We further examined fi ndings for lung cancer according to tumor histology (small-cell versus non -small-cell), given the poorer prognosis of the former group ( 21 ) . Nine (7%) second lung cancers and 280 (16%) fi rst lung cancers were small cell in type ( P = .15). The rate ratio of death due to a second small-cell lung cancer was nearly twice that observed for a fi rst small-cell lung cancer (RR = 1.95, 95% CI = 0.92 to 4.13); that corresponding to non -small-cell lung cancer was 1.12 (95% CI = 0.96 to 1.47) ( P heterogeneity = .17). Results for all-cause mortality showed a similar pattern of greater rate ratio for second compared to fi rst small-cell lung cancer than for second compared to fi rst non-small-cell lung cancer.
No statistically signifi cant differences were observed for cancer-specifi c and all-cause mortality for all sites combined according to prior testicular cancer histology (seminoma, nonseminoma), stage, age at diagnosis, initial course of treatment, years since testicular cancer diagnosis, age, year of diagnosis, or initial course of treatment of second and matching fi rst cancers. However, rate ratios of cancer-specifi c and all-cause mortality in second cancer patients declined with calendar period of testicular cancer diagnosis. For example, rate ratios for second cancer -specifi c mortality were 1.29 (95% CI = 1.02 to 1.64), 1.06 (95% CI = 0.83 to 1.35), and 0.70 (95% CI = 0.49 to 1.02) among testicular cancer patients who were diagnosed during 1973 -1979, 1980 -1989, and 1990 -2002 , respectively ( P heterogeneity = .02). Similar patterns were evident for all-cause mortality. Rate ratios for cancer-specifi c and allcause mortality were generally elevated regardless of time since testicular cancer diagnosis among those diagnosed during 1973 -1979. Elevations in second cancer -specifi c and all-cause mortality among men who were diagnosed with testicular cancer in 1973 -1979 were derived largely from sites that were in the radiotherapy treatment fi elds for testicular cancer during that era (i.e., subdiaphragmatic and thoracic cancers) ( Table 4 ). Rate ratios ( ≤ 1979, 1980 -1984, 1985 -1989, 1990 -1994, 1995 -1999, 2000 -2002) , and stage (localized, regional, distant for nonlymphohematopoietic malignancies other than prostate cancer; localized, regional/distant for prostate cancer; and unstaged for non-chronic lymphocytic leukemias). † Log-rank test (two-sided) of differences in survival distributions of second cancers after testicular cancer and matched primary cancers. P values are not adjusted for multiple comparisons. ‡ Upper confidence limit could not be calculated.
for all-cause mortality were 1.44 (95% CI = 1.13 to 1.83) and 1.46 (95% CI = 1.02 to 2.10) for these groups, respectively. Seventy-fi ve percent of subdiaphragmatic cancers and 81% of thoracic cancers were seen in survivors of testicular seminoma, which was more frequently treated with radiotherapy than nonseminoma (85% versus 29%). Among those who were known to have received radiotherapy as part of the fi rst course of treatment for testicular cancer, the rate ratio for all-cause mortality following second subdiaphragmatic and thoracic cancers combined compared with similar fi rst cancers was higher following nonseminoma (RR = 2.47; 95% CI = 1.07 to 5.69) than seminoma (RR = 1.35; 95% CI = 1.06 to 1.73), although differences according to testicular cancer histology were not statistically signifi cant ( P = .17). With regard to specifi c second cancer sites in the radiotherapy fi elds for testicular cancer diagnosed during 1973 -1979, nonstatistically signifi cant increases in mortality were observed following second cancers of the colon/rectum/anus or the pancreas ( Table 4 ) . A statistically signifi cant increase in cancer-specifi c mortality was noted for second kidney cancer, although it was based on only two deaths (RR = 5.8, 95% CI = 1.10 to 31.1). The rate ratios for mortality following a second lung cancer were also statistically signifi cantly elevated compared with comparable fi rst lung cancers (e.g., for all-cause mortality, RR = 1.65, 95% CI = 1.12 to 2.42); the difference in survival distributions for fi rst and second lung cancers was of borderline statistical signifi cance ( P = .08). No elevations in mortality were observed following second cancers of the stomach, bladder, or prostate (data not shown).
Additional adjustment for initial treatment of second and matched fi rst cancers did not substantially change the rate ratio for all-cause mortality for subdiaphragmatic sites combined or for specifi c subdiaphragmatic sites. However, adjustment for initial treatment resulted in a slight reduction in the rate ratio for allcause mortality following lung cancer , from 1.65 (95% CI = 1.12 to 2.42) to 1.53 (95% CI = 1.01 to 2.33). Second lung cancers among testicular cancer survivors diagnosed during 1973 -1979 were somewhat less frequently treated with radiotherapy than were fi rst lung cancers (40% versus 57%) ( P = .07). 
Discussion
The current investigation represents the first large populationbased study of testicular cancer survivors to examine mortality/ survival after a second cancer diagnosis compared with first cancers of the same type. For all sites combined, cancer-specific and allcause mortality following a second cancer were not statistically significantly greater than mortality for comparable first cancers. This was also true for most specific cancer sites and subgroups. However, we noted a pattern of increased cancer-specific and all-cause mortality for second cancers in the radiotherapy field for testicular cancer diagnosed during 1973 -1979, specifically cancers of the lung, colon/rectum/anus, pancreas, and kidney. Cancer-specific and allcause mortality for second cancers in the radiotherapy field following testicular cancer diagnosed in 1980 or later were comparable to those of first cancers. Changes in the treatment of testicular cancer have occurred during the past 25 years ( 18 ) . With the advent of platinum-based chemotherapy in the early 1970s, increasing numbers of nonseminoma patients were managed with retroperitoneal lymph node dissection and chemotherapy rather than with radiotherapy. Radiotherapy doses were generally higher for treatment of nonseminoma than seminoma ( 4 ). Whereas subdiaphragmatic radiotherapy has persisted as the standard treatment for seminoma patients, doses and fi eld sizes have been reduced ( 18 , 22 -25 ) , with a commensurate lowering of doses received by various organs ( 4 ) . Prophylactic irradiation of the mediastinum in seminoma patients has declined over time ( 22 ) . These changes in treatment of testicular cancer may explain the pattern of increased cancer-specifi c and all-cause mortality for selected sites in the radiotherapy fi eld following testicular cancer diagnosed during 1973 -1979 but not later. In support of this hypothesis, among those who were known to have received radiation treatment for testicular cancer, we found some evidence of higher mortality among second cancers in the radiotherapy fi eld following nonseminoma than seminoma testicular cancer, consistent with the higher doses of radiation received by patients with nonseminomas.
An analysis of cause-specifi c or all-cause mortality that is not adjusted for type of initial treatment for the second cancer (or matched fi rst cancer) more fully refl ects the impact of the initial testicular cancer diagnosis than an analysis adjusted for initial treatment of the second and fi rst cancer because the management of the initial testicular cancer may have limited the range of possible treatment options for the second cancer. Nevertheless, we also conducted analyses adjusted for the type of treatment of the second cancer (and matched fi rst cancers) to determine whether increased mortality could be explained by differences in initial treatment for the second cancers. We found little evidence that concern over complications from radiation fi brosis ( 26 ) following testicular cancer treatment discouraged surgical treatment of second cancers, but there was some indication that radiotherapy treatment for second thoracic cancers was less frequent than for matched fi rst cancers among those whose testicular cancer was diagnosed during 1973 -1979 . This situation may refl ect the reluctance of radiation oncologists to reirradiate tissue that had previously received high doses of radiation ( 6 ) . These differences in initial course of treatment accounted for only a small part of the elevation in mortality following second lung cancers in this group. Differences in subsequent treatment, the use of lower than optimal radiation doses due to concern regarding normal tissue tolerance to reirradiation, or second tumors that are either biologically more aggressive or less responsive to treatment could also contribute to the observed excess mortality following second cancers in the radiotherapy fi eld for testicular cancer diagnosed during this early time period. For example , widespread genomic instability has been reported in lung tumors after radiotherapy for Hodgkin lymphoma ( 27 ) .
Previous studies in testicular cancer patients addressed mortality due to second cancers compared with expected rates in the general population, but not mortality from comparable fi rst cancers ( 22 , 28 -30 ) . Other studies of survival after a second cancer diagnosis compared with fi rst cancers were limited to a specifi c second cancer following a wide variety of fi rst cancers or following a specifi c fi rst cancer other than testicular cancer ( 31 -34 ) . A previous study concluded that acute myeloid leukemia that occurs after chemotherapy or radiotherapy for a wide variety of fi rst cancers is either biologically more aggressive or less responsive to treatment than fi rst primary acute myeloid leukemia ( 31 ). Although we did not identify a statistically signifi cant increase in mortality from acute myeloid leukemia following testicular cancer compared with fi rst cancers, the numbers were small, precluding defi nitive conclusions. Similar to the overall lung cancer results, a previous study found that operable second non -small-cell lung cancers had a prognosis similar to comparable fi rst lung cancers ( 32 ) .
The study had several potential limitations, including the small number of second cancers for each specifi c cancer site. Thus, for most specifi c cancer sites, we were unable to rule out adverse survival effects for second cancers relative to comparable fi rst cancers. The lack of complete and precise treatment information limited our ability to determine whether differences in mortality for selected second cancers compared with fi rst cancers were due to differences in dose of radiation, type and dose of chemotherapy, extent of surgery, adjuvant treatment modalities, or treatment beyond the initial course of therapy. The SEER program does not collect information about lifestyle risk factors that may be associated with cancer incidence and prognosis, e.g., tobacco, alcohol, diet, and obesity. Thus, although we assumed that these factors and more subtle differences in tumor characteristics than are evident in the broad staging classifi cation or morphologic classifi cation used by SEER were distributed similarly between the second and fi rst cancer cohorts, we cannot be sure that this assumption is correct . It is possible that within the broad staging scheme that we used for matching, the second cancers had on average more favorable prognostic profi les than the fi rst cancers due to increased surveillance in testicular cancer survivors, resulting in some underestimation of the rate ratios. In addition, subsequent cancers are not recorded in the SEER database for those who move from their original SEER reporting area, a factor most likely to be important for metropolitan areas, for the longest follow-up observation periods, and for young adults ( 35 ) . However, the results are not likely to be materially affected by this last point because we found no major differences in mortality for second cancers compared with fi rst cancers according to age at or time since testicular cancer diagnosis. It is also unlikely that the development of more (or less) aggressive second malignancies (and thus, survival after such a diagnosis) would be related to the propensity of a testicular cancer survivor to migrate from SEER areas. Lack of precision in cause-of-death coding may have impaired our ability to link cause of death to a certain cancer, but this happened for only a small portion of patients and was not differential between second and fi rst cancers. Finally, there were very few statistically signifi cant fi ndings, even though our reported P values were not adjusted for multiple comparisons. Except in cases for which we had prior hypotheses, such as that radiation treatment for testicular cancer could adversely affect survival from second cancers, we regarded the P values less as formal hypothesis tests than as descriptive statistics that could point to interesting fi ndings.
Our study also had a number of strengths. All patients were identifi ed from population-based registries, which use standardized methods to collect data for fi rst and second cancers. We were also able to identify a relatively large number of second cancers after testicular cancer and match them to comparable fi rst cancers.
In summary, cancer-specifi c and all-cause mortality following a second cancer diagnosis in testicular cancer patients were not statistically signifi cantly greater than mortality in comparable fi rst cancers for all cancer sites combined and for most specifi c cancer sites. We did note a pattern of increased cancer-specifi c and allcause mortality for selected sites in the radiotherapy fi eld for testicular cancer diagnosed during 1973 -1979 , suggesting that treatment of testicular cancer by radiotherapy during that era may have negatively impacted survival from subsequent cancers. Survival for second cancers following testicular cancer that was diagnosed during 1980 -2002 was similar to that of comparable fi rst cancers, suggesting that treatment regimens for testicular cancer used since 1980 have not adversely affected survival from subsequently diagnosed cancers.
